Headache and Migraine

Neurology News Network for the week ending February 8, 2020.

The director of headache services at NYU Langone discussed the 2019 American College of Emergency Physicians guidelines on acute nontraumatic headache in the emergency department.

Join NeurologyLive and the Women Neurologists Group on Twitter to celebrate women in neurology on National Women Physicians Day.

Neurology News Network for the week ending February 1, 2020.

The drug will be available in 50 mg and 100 mg oral tablets in pharmacies across the US in the coming days.

Teva announced that the Ajovy autoinjector is expected to be available to patients in the coming months.

Findings from a study revealed that 50% of strokes in adolescents remained cryptogenic, sparking the need for multidisciplinary collaboration on prevention and management.

Neurology News Network for the week ending January 27, 2020.

The Headaterm TENS device was shown to decrease pain at an 11.8% better rate than many acute migraine medications used in the emergency department in randomized trials, with data suggesting it is both effective and fast-acting.

Neurology News Network for the week ending January 18, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending January 17, 2020.

After first-step data suggested that one small molecule CGRP receptor antagonist and a monoclonal antibody against CGRP were successful and safe together in migraine. One of the study authors, Kathleen Mullin, MD, discussed the data.

Biohaven’s small molecule CGRP receptor antagonist rimegepant has displayed safety and efficacy in a small cohort of patients with migraine using it alongside erenumab.

Those achieving ≥50% response attained migraine reductions nearly double that of the full cohort, with data possibly providing context for setting realistic patient expectations regarding the spectrum of response.

Neurology News Network for the week ending January 11, 2020.

New 52-week data from an extension study has suggested that recently FDA-approved ubrogepant (Ubrelvy; Allergan) is safe and tolerable, with minimal treatment-related adverse events with 2 doses assessed.

The guidelines included a review of 23 studies, suggesting that patients with normal neurological examinations do not require neuroimaging assessments as part of migraine treatment.

The oral, dual-mechanism therapy from Axsome Therapeutics met both of its primary end points in the phase 3 MOMENTUM trial in acute migraine, and is expected to be filed with the FDA.

Lasmiditan was efficacious across a number of doses in patients with migraine regardless of prior good or insufficient response to triptan administration.

With a differential diagnosis that varies from patient to patient, identifying and treating vestibular migraine continues to challenge even the most experienced clinicians.

The approvals introduced several new classes of drugs, including the ditans and gepants in migraine, as well as novel formulations that can ease the administration of treatments for Parkinson disease and epilepsy.

The director of the Jefferson Headache Center at Thomas Jefferson University detailed the most notable achievements from 2019, and what to expect in the coming year.

Catch up on some of our most popular Peer Exchange panels with experts in the field, including discussions on epilepsy, migraine, multiple sclerosis, and more.

Catch up on some of our most popular video interviews with leaders in the field, including discussions with Imad Najm, MD, James Leverenz, MD, Richard Isaacson, MD, and more.

Branded as Ubrelvy, Allergan’s oral calcitonin gene-related peptide antagonist is the first-in-class to be approved for this indication.